Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

2016115 citationsJournal Article

Authors

Good health and well-being

Published in: Annals of Oncology

Volume 28, Issue 3, pp. 497-504

Field-Weighted Citation Impact: 5.21